Volume: 9 Issue: 3
Year: 2021, Page: 3-7, Doi: https://doi.org/10.47799/pimr.0903.02
Received: Sept. 27, 2021 Accepted: Oct. 26, 2021 Published: Oct. 26, 2021
Objective: To review the literature on equianalgesic efficacy and better safety(less respiratory depression and gastrointestinal dysfunction) of oliceridine versus opioid analgesic in moderate to severe postoperative pain.
Methodology: A comprehensive literature search was conducted in PubMed (January 2021 to March 2021) using keywords as ‘oliceridine’, ‘ligand biased mu receptor agonist’, ‘acute postoperative pain’, ‘conventional opioids’ and ‘morphine’. All English language full text pre-clinical and clinical research articles were searched. In addition, other data source was from ClinicalTrial. Gov.
Data Synthesis: Oliceridine is a novel selective µ (mu)-receptor G-protein pathway modulator. G protein biased mu receptor agonists are a new class of opioids exhibiting analgesic properties at par to morphine with less respiratory depressant properties. Oliceridine a first-in-class intravenous (IV) analgesic has received the US FDA approval in August 2020, for management of moderate to severe acute pain in adults. The drug can be administered in cases where the pain is severe enough to require an intravenous opioid and when alternative treatments become inadequate. Oliceridine is an opioid agonist with a rapid onset of action within two to five minutes, was administered via clinician-administered bolus dosing, patient-controlled analgesia (PCA), or a combination of the two. Bolus dosing was initiated at 1 to 2 mg, with supplemental doses of 1 to 3 mg every one to three hours, as needed, based on individual patient need and previous response to oliceridine in management of acute post-operative pain. If oliceridine was administered via PCA, the loading dose was 1.5 mg, the demand dose was 0.5 mg, and the lockout interval (repeat dose)was six minutes. The clinically relevant concentration range of 0 to 35 ng/ml. It is indicated for short-term use only & limited to hospitals or other controlled clinical settings. Oliceridine requires no dosage adjustments in patients with renal impairment as well as in patient with significant medical complications. Therefore, opioids that bias towards G-protein and away from β arrestin signaling should produce analgesia with reduced side effects.
Keywords: Oliceridine, ligand biased mu receptor agonist, acute postoperative pain, conventional opioids, morphine.
Machelska, H & Celik, M Ö . 2018. Advances in achieving opioid analgesia without side effects. Front Pharmacol 9:1388.
Ayad, S, Demitrack, M A, Burt, D A, Michalsky C Wase, L, Fossler, M J & Khanna, A K . 2020. Evaluating the Incidence of Opioid-Induced Respiratory Depression Associated with Oliceridine and Morphine as Measured by the Frequency and Average Cumulative Duration of Dosing Interruption in Patients Treated for Acute Postoperative Pain. Clinical Drug Investigation 40:755–764.
Ayad, S, Khanna, A K, Iqbal, S U & Singla, N . 2019. Characterisation and monitoring of postoperative respiratory depression: current approaches and future considerations. Br J Anaesth 123(3):378–91.
Dahan, A, Niesters, M, Velzen, & Olofsen, E . 2020. Benefit and Risk Evaluation of Biased μ-Receptor Agonist Oliceridine versus Morphine. Anesthesiology 133:559–568.
Raehal, K M, Walker, J K & Bohn, L M . 2005. Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther 314:1195–201.
Mores, K L, Cummins, B R, Cassell, R J & Van Rijn, R M . 2019. A review of the therapeutic potential of recently developed G protein-biased kappa agonists. Front Pharmacol 10:407.
Violin, J D, Crombie, A L, Soergel, D G & Lark, M W . 2014. Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol Sci 35:308–324.
Oliceridine, - Fda . 2021. https://www.fda.gov/media/121230/download
Nafziger, A N, Arscott, K A, Cochrane, K, Skobieranda, F, Burt, D A & Fossler, M J . 2020. The Influence of Renal or Hepatic Impairment on The Pharmacokinetics, Safety, And Tolerability Of Oliceridine. Clin Pharmacol Drug Dev 9(5):639–650.
Fossler, M J, Sadler, B M, Farrell, C, Burt, D A, Pitsiu, M & Skobieranda, F . 2018. Oliceridine, a novel G protein–biased ligand at the μ‑Opioid receptor, demonstrates a predictable relationship between plasma concentrations and pain relief. II: Simulation of potential phase 3 study designs using a pharmacokinetic/pharmacodynamic model. J Clin Pharm 58:762–770.
Viscusi, E R, Skobieranda, F, Soergel, D G, Cook, E, Burt, D A & Singla, N . 2019. APOLLO-1: A randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the μ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. J Pain Res 12:927–970.
Singla, N K, Skobieranda, F & Soergel, D G . 2019. APOLLO-2:a randomized, placebo and active-controlled phase III study investigating oliceridine (TRV 130), a G protein-biased ligand at the μ-opioid receptor, for management of moderate tosevere acute pain following abdominoplasty. Pain Practice 19(7):715–731.
Bergese, S D, Brzezinski, M & Hammer, G B . 2019. ATHENA: a phase 3, open-label study of the safety and effectiveness of oliceridine (TRV130), A G-protein selective agonist at the μ-opioid receptor, in patients with moderate to severe acute pain requiring parenteral opioid therapy. Journal of Pain Research 12:3113–3126.
Khanna, A K, Bergese, S D, Jungquist, C R, Morimatsu, H, Uezonos, & Lee, S . 2020. Prediction of opioid-induced respiratory depression on inpatient wards using continuous capnography(PRODIGY)group collaborators.Prediction of opioid induced respiratory depression on inpaptients wards using continuous capnography a and oximetry: an international prospective,observational trial. Anesth Analg 131(4):1012–1024.
Shafi, S, Collinsworth, A W & Copeland, L A . 2018. Association of opioid-related adverse drug events with clinical and cost outcomes among surgical patients in a large integrated. Health care delivery system. JAMA Surgery 153(8):757–763.
Lin, Y, Zhang, X, Li, L, Wei, M, Zhao, B & Wang, X . 2019. High-flow nasal cannula oxygen therapy and hypoxia during gastroscopy with propofol sedation: A randomized multicenter clinical trial. Gastroint Endosc 90:591–601.
Goudra, B & Singh, P M . 2020. Oliceridine and its potential to revolutionize GI endoscopy sedation. Saudi J Anaesth 14:349–54.
Yin, S, Hong, J, Sha, T, Chen, Z, Guo, Y & Li, C . 2019. Efficacy and tolerability of sufentanil, dexmedetomidine, or ketamine added to propofol-based sedation for gastrointestinal endoscopy in elderly patients: A prospective,randomized, controlled trial. Clin Ther 41:1864–77.
Advani U, Prakash R, Swami P, Sharma N, Jain C, Jain M. Oliceridine as a Novel Selective mu-receptor G-protein Pathway Modulator: A Narrative review. Perspectives in Medical Research. 2021;9(3):3-7 DOI: 10.47799/pimr.0903.02